TY  - JOUR
AU  - Wang, Yanling
AU  - Yang, Xiaoxuan
AU  - Ma, Jia
AU  - Chen, Shenglan
AU  - Gong, Ping
AU  - Dai, Ping
TI  - Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer.
JO  - Heliyon
VL  - 10
IS  - 5
SN  - 2405-8440
CY  - London [u.a.]
PB  - Elsevier
M1  - DKFZ-2024-00491
SP  - e27077
PY  - 2024
N1  - #LA:E055#
AB  - Thyroid Dysfunction (TD) is a common immune-related adverse events (irAEs) in the treatment of advanced lung cancer with programmed cell death protein 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors, with incidence accounting for 6-8
KW  - Advanced lung cancer (Other)
KW  - Efficacy (Other)
KW  - Immune checkpoint inhibitors (Other)
KW  - PD-1/PD-L1 inhibitors (Other)
KW  - Thyroid dysfunction (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38449616
C2  - pmc:PMC10915392
DO  - DOI:10.1016/j.heliyon.2024.e27077
UR  - https://inrepo02.dkfz.de/record/288826
ER  -